Cell Signaling Technology Logo
View Featured Offers >>
1% for the planet logo
  1. Products /
  2. Primary Antibodies /
  3. FGF Receptor 2IIIb (FPR2-D) Mouse mAb
Trial Size Available Flag
Recombinant Flag
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

FGF Receptor 2IIIb (FPR2-D) Mouse mAb #52742

Filter:
  • WB
  • IHC

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 92, 145
    Source/Isotype Mouse IgG2a kappa
    Application Key:
    • WB-Western Blotting 
    • IHC-Immunohistochemistry 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    IHC Leica Bond 1:200 - 1:800

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    FGF Receptor 2IIIb (FPR2-D) Mouse mAb recognizes endogenous levels of total FGFR2 protein. This antibody specifically detects the FGFR2IIIb isoform (UniProt P21802-3).

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues of human FGFR2IIIb protein.

    Background

    Fibroblast growth factors (FGFs) produce mitogenic and angiogenic effects in target cells by signaling through cell surface receptor tyrosine kinases. There are four members of the FGF receptor family (FGFR1-4) that share between 56 and 71% sequence identity (1). Following ligand binding and dimerization, the receptors are phosphorylated at specific tyrosine residues, initiating downstream signaling pathways (2). Mutations in the FGFR2 gene cause syndromes characterized by facial and limb defects, including LADD Syndrome, Crouzon Syndrome, Beare-Stevenson Cutis Gyrata Syndrome, Pfeiffer Syndrome, Apert Syndrome, and Jackson-Weiss Syndrome (3-5). FGFR2 gene amplification and other mutations, as well as altered expression, have been observed in cases of gastric, endometrial, and breast cancer (6). FGFR2 has two primary isoforms, FGFR2IIIc (isoform1, also known as BEK) and FGFR2IIIb (isoform 3, also known as FGFR2b) that are generated through alternative spicing of the third immunoglobulin-like domain crucial for ligand binding. The isoforms differ in tissue distribution and biological activities (7,8). FGFR2IIIb is mainly detected in epithelial cells and can be overexpressed in estrogen receptor-positive breast cancer and gastric cancer (9-11). It preferentially binds to the ligands FGF7, FGF10, and FGF22, with subsequent receptor homodimerization activating downstream signaling pathways including PI3K/Akt and RAS-MAPK (12-14). When overexpressed, FGFR2IIIb promotes aberrant signaling, leading to tumor cell proliferation (15).
    1. Itoh, N. and Ornitz, D.M. (2004) Trends Genet 20, 563-9.
    2. Farrell, B. and Breeze, A.L. (2018) Biochem Soc Trans 46, 1753-1770.
    3. Jeftha, A. et al. (2004) J Clin Pediatr Dent 28, 173-6.
    4. Wilkinson, C.C. et al. (2012) Childs Nerv Syst 28, 1221-6.
    5. Slavotinek, A. et al. (2009) Am J Med Genet A 149A, 1814-7.
    6. Katoh, M. (2009) J Invest Dermatol 129, 1861-7.
    7. Coutts, J.C. and Gallagher, J.T. (1995) Immunol Cell Biol 73, 584-9.
    8. Muh, S.J. et al. (2002) J Biol Chem 277, 50143-54.
    9. Dix-Peek, T. et al. (2024) Biology (Basel) 13, 920. doi: 10.3390/biology13110920.
    10. Yashiro, M. et al. (2021) Sci Rep 11, 4698.
    11. Rha, S.Y. et al. (2025) JCO Precis Oncol 9, e2400710.
    12. Zhang, X. et al. (2006) J Biol Chem 281, 15694-700.
    13. Ahn, S. et al. (2016) Mod Pathol 29, 1095-103.
    14. Catenacci, D.V.T. et al. (2020) J Clin Oncol 38, 2418-2426.
    15. Gordon, A. et al. (2022) Onco Targets Ther 15, 1183-1196.

    Database Links

    UniProt ID: P21802-3


    Entrez-Gene Id: 2263


    Limited Uses

    Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

    Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

    For Research Use Only. Not for Use in Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    This product, the process of its manufacture, or its use, may be covered by one or more U.S. Patents, including U.S. Patent Nos. 9,834,609 and 10,138,301.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.